Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$2.77M$2.77M+96.4% vs Q2 2024 Net Income-$30.46M-$30.46MN/M vs Q2 2024 EPS Diluted-$0.13-$0.13N/M vs Q2 2024 Operating Income-$19,780,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,553,000N/M Margins · derivedOperating margin-715.4%−298.7 pt vs Q2 2024
Net margin-1101.8%−692.7 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end